Related Experiment Video
Updated: Aug 11, 2026
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
Published on: March 1, 2022
Progression from hypertension to heart failure. Mechanisms and management
1Department of Cardiology, University of Hull, Castle Hill Hospital, Kingston-upon-Hull, UK. J.G.Cleland@medschool.hull.ac.uk
Insights
Hypertension increases heart failure risk. Beta-blockers like carvedilol may prevent heart failure by lowering blood pressure, reducing left ventricular hypertrophy, and improving outcomes after myocardial infarction.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension is a significant risk factor for heart failure (HF).
- Mechanisms linking hypertension to HF, including left ventricular hypertrophy (LVH), require further clarification.
- Antihypertensive therapy reduces HF risk, but optimal agents and mechanisms remain unclear.
Purpose of the Study:
- To explore the theoretical benefits of beta-blockers for preventing HF in hypertensive patients.
- To evaluate carvedilol as a potential agent for HF prevention due to its unique properties.
Main Methods:
- Theoretical review of beta-blocker mechanisms in hypertension and HF.
- Examination of carvedilol's pharmacological profile, including alpha-1 blockade and antioxidant effects.
- Analysis of existing evidence on beta-blockers, myocardial infarction (MI), and HF prognosis.
Main Results:
- Beta-blockers offer theoretical advantages for HF prevention beyond blood pressure control.
- Non-selective beta-blockers demonstrate reduced long-term mortality post-MI.
- Carvedilol's ancillary properties and proven benefits in HF suggest its suitability for preventing HF in hypertensive individuals.
Conclusions:
- Beta-blockers, particularly non-selective agents like carvedilol, are promising for preventing HF in hypertensive patients.
- Carvedilol's multifaceted actions may offer superior benefits in managing hypertension-related cardiovascular risks.
- Further research may confirm carvedilol's role in reducing HF incidence and improving outcomes.
Abstract:
Patients with hypertension are at increased risk of developing heart failure (HF), but the mechanisms by which hypertension leads to HF have not been clarified [although left ventricular hypertrophy (LVH) is clearly a predictor of an increased risk of HF]. Similarly, although antihypertensive therapy has been shown to reduce the risk of HF in hypertensive patients, it is not known how this benefit is produced and, currently, there is no clear evidence that any class of antihypertensive agent is more effective than any other in this respect. On theoretical grounds, beta-blockers would be expected to be ideal agents for the prevention of HF in hypertensive patients. In addition to control of blood pressure and regression of LVH, they have clear benefits on morbidity and mortality after myocardial infarction (MI), which probably plays a major role in the development of HF in hypertensive patients, and on the prognosis of HF itself. A reduction in long-term mortality after MI has been demonstrated only for non-selective beta-blockers. Carvedilol, a non-selective beta-blocker which also has other ancillary properties including alpha-1-receptor blockade and antioxidant effects and a favourable metabolic profile, may be an appropriate choice for the prevention of HF in hypertensive patients. This is reinforced by the salutary benefits of carvedilol for the reduction in the morbidity and mortality of HF itself.
Related Concept Videos
01:17Pathophysiology of Heart Failure
01:27Heart Failure I: Introduction
01:29Heart Failure II: Pathophysiology
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:30Heart Failure V: Medical Management
01:30Heart Failure VII: Nursing Interventions